Skip to main content
K

KOMIPHARM INTERNATIONAL CO., LTD. — Investor Relations & Filings

Ticker · 041960 ISIN · KR7041960006 KO Manufacturing
Open in API
Filings indexed 325 across all filing types
Latest filing 2024-08-06 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 041960

About KOMIPHARM INTERNATIONAL CO., LTD.

https://komipharm.co.kr/en/

Komipharm International Co., Ltd. is a biopharmaceutical company engaged in the development, manufacturing, and sale of products for both animal and human health. Its Animal Health Division provides a portfolio of veterinary vaccines, pharmaceuticals, and disinfectants. The company's Pharmaceutical Division is dedicated to the research and development of novel therapeutic agents, with key research areas including anticancer drugs and treatments for cancer-related pain and autoimmune diseases. Leveraging extensive experience, the company focuses on intensive R&D to expand its presence in the global bio-industry.

Recent filings

Filing Released Lang Actions
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for Komipharm, covering the period from January 1, 2024, to June 30, 2024. It contains comprehensive financial statements, management discussion and analysis, and detailed business operations information. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2024
2024-08-06 Korean
자기주식취득결과보고서
Transaction in Own Shares Classification · 1% confidence The document is a '자기주식취득결과보고서' (Report on the Results of Treasury Stock Acquisition) filed with the Financial Supervisory Service (FSS) in South Korea. It details the specific dates, quantities, and prices of shares repurchased by the company (Komipharm) over a defined period. This falls under the category of a company reporting its own share buyback activities.
2024-07-31 Korean
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 1% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange (KRX). It specifically details a 'Decision to Acquire Treasury Shares' (자기주식 취득 결정), which is a corporate action involving the company buying back its own shares. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct category for reports of a company buying back its own shares.
2024-07-31 Korean
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 1% confidence The document is a formal regulatory filing titled '주요사항보고서(자기주식 취득 결정)' which translates to 'Major Report (Decision to Acquire Treasury Shares)'. It details the company's (Komipharm) board decision to buy back its own shares, including the number of shares, the purpose, the method, and the financial limits. This falls directly under the definition of 'Transaction in Own Shares' (POS).
2024-05-29 Korean
자기주식취득결과보고서
Transaction in Own Shares Classification · 1% confidence The document is a '자기주식취득결과보고서' (Report on the Results of Treasury Stock Acquisition) filed with the Financial Supervisory Service (FSS) in South Korea. It details the specific dates, quantities, and prices of shares repurchased by the company (Komipharm) over a defined period. This falls directly under the category of a company reporting its own share buyback activities.
2024-05-28 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company Komipharm, covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial statements, management discussion and analysis, and operational data, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-10 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.